Replies to post #5385 on GTC Biotherapeutics (fka GTCB)

[ThomasS]

I agree; however, "good chance" and "slam-dunk" are two entirely different concepts.
ATRYN's future depends on the DIC indication; we will not even have PII data for quite awhile... neither will a potential partner.